|
Atomistry » Chlorine » PDB 5jzs-5k9d » 5k7k | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Atomistry » Chlorine » PDB 5jzs-5k9d » 5k7k » |
Chlorine in PDB 5k7k: Design and Optimization of Biaryl Ether Aryl Sulfonamides As Selective Inhibitors of NAV1.7: Discovery of Clinical Candidate Pf-05089771Enzymatic activity of Design and Optimization of Biaryl Ether Aryl Sulfonamides As Selective Inhibitors of NAV1.7: Discovery of Clinical Candidate Pf-05089771
All present enzymatic activity of Design and Optimization of Biaryl Ether Aryl Sulfonamides As Selective Inhibitors of NAV1.7: Discovery of Clinical Candidate Pf-05089771:
1.14.13.80; Protein crystallography data
The structure of Design and Optimization of Biaryl Ether Aryl Sulfonamides As Selective Inhibitors of NAV1.7: Discovery of Clinical Candidate Pf-05089771, PDB code: 5k7k
was solved by
N.Swain,
J.Chrencik,
with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:
Other elements in 5k7k:
The structure of Design and Optimization of Biaryl Ether Aryl Sulfonamides As Selective Inhibitors of NAV1.7: Discovery of Clinical Candidate Pf-05089771 also contains other interesting chemical elements:
Chlorine Binding Sites:
The binding sites of Chlorine atom in the Design and Optimization of Biaryl Ether Aryl Sulfonamides As Selective Inhibitors of NAV1.7: Discovery of Clinical Candidate Pf-05089771
(pdb code 5k7k). This binding sites where shown within
5.0 Angstroms radius around Chlorine atom.
In total only one binding site of Chlorine was determined in the Design and Optimization of Biaryl Ether Aryl Sulfonamides As Selective Inhibitors of NAV1.7: Discovery of Clinical Candidate Pf-05089771, PDB code: 5k7k: Chlorine binding site 1 out of 1 in 5k7kGo back to![]() ![]()
Chlorine binding site 1 out
of 1 in the Design and Optimization of Biaryl Ether Aryl Sulfonamides As Selective Inhibitors of NAV1.7: Discovery of Clinical Candidate Pf-05089771
![]() Mono view ![]() Stereo pair view
Reference:
N.A.Swain,
D.Batchelor,
S.Beaudoin,
B.M.Bechle,
P.A.Bradley,
A.D.Brown,
B.Brown,
K.J.Butcher,
R.P.Butt,
M.L.Chapman,
S.Denton,
D.Ellis,
S.R.G.Galan,
S.M.Gaulier,
B.S.Greener,
M.J.De Groot,
M.S.Glossop,
I.K.Gurrell,
J.Hannam,
M.S.Johnson,
Z.Lin,
C.J.Markworth,
B.E.Marron,
D.S.Millan,
S.Nakagawa,
A.Pike,
D.Printzenhoff,
D.J.Rawson,
S.J.Ransley,
S.M.Reister,
K.Sasaki,
R.I.Storer,
P.A.Stupple,
C.W.West.
Discovery of Clinical Candidate 4-[2-(5-Amino-1H-Pyrazol-4-Yl) -4-Chlorophenoxy]-5-Chloro-2-Fluoro-N-1, 3-Thiazol-4-Ylbenzenesulfonamide (Pf-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides As Selective Inhibitors of NAV1.7. J. Med. Chem. V. 60 7029 2017.
Page generated: Sat Jul 12 03:54:52 2025
ISSN: ISSN 1520-4804 PubMed: 28682065 DOI: 10.1021/ACS.JMEDCHEM.7B00598 |
Last articlesZn in 4NW7Zn in 4NU7 Zn in 4NTN Zn in 4NTM Zn in 4NUO Zn in 4NTL Zn in 4NTK Zn in 4NQA Zn in 4NT9 Zn in 4NRZ |
© Copyright 2008-2020 by atomistry.com | ||
Home | Site Map | Copyright | Contact us | Privacy |